Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia

NCT01809223 is registered in ClinicalTrials.gov with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor.

NCT NCT01809223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01809223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
August 31, 2012
Completion date
March 31, 2015
Enrollment
176 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

choroid neovascularization secondary to degenerative myopia